Skip to main content
NCBI home page
The AAPS Journal logoLink to The AAPS Journal
. 2006 Jul 21;8(3):E466–E478. doi: 10.1208/aapsj080355

Issues related to targeted delivery of proteins and peptides

Yingjuan Lu 1,✉, Jun Yang 2, Emanuela Sega 2
PMCID: PMC2761053  PMID: 17025264

Abstract

While modern genomic and proteomic technology enables rapid screening of novel proteins and peptides as potential drug candidates, design of delivery systems for these biologics remains challenging especially to achieve site-specific pharmacological actions. This article discusses the issues associated with targeted delivery of protein and peptide drugs at physiochemical, physiological, and intracellular levels with a special focus on cancer therapy.

Keywords: targeted delivery, protein therapeutics, peptide therapeutics, cancer therapy

Full Text

The Full Text of this article is available as a PDF (265.5 KB).

References

  • 1.Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug Discov. 2003;2:347–360. doi: 10.1038/nrd1088. [DOI] [PubMed] [Google Scholar]
  • 2.Ruoslahti E. Specialization of tumour vasculature. Nat Rev Cancer. 2002;2:83–90. doi: 10.1038/nrc724. [DOI] [PubMed] [Google Scholar]
  • 3.Maeda H. SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. Adv Drug Deliv Rev. 2001;46:169–185. doi: 10.1016/S0169-409X(00)00134-4. [DOI] [PubMed] [Google Scholar]
  • 4.Schally AV. Luteinizing hormone-releasing hormone analogs: their impact on the control of tumorigenesis. Peptides. 1999;20:1247–1262. doi: 10.1016/S0196-9781(99)00130-8. [DOI] [PubMed] [Google Scholar]
  • 5.Eklund JW, Kuzel TM. Denileukin diftitox: a concise clinical review. Expert Rev Anticancer Ther. 2005;5:33–38. doi: 10.1586/14737140.5.1.33. [DOI] [PubMed] [Google Scholar]
  • 6.Stern M, Herrmann R. Overview of monoclonal antibodies in cancer therapy: present and promise. Crit Rev Oncol Hematol. 2005;54:11–29. doi: 10.1016/j.critrevonc.2004.10.011. [DOI] [PubMed] [Google Scholar]
  • 7.Hertler AA, Frankel AE. Immunotoxins: a clinical review of their use in the treatment of malignancies. J Clin Oncol. 1989;7:1932–1942. doi: 10.1200/JCO.1989.7.12.1932. [DOI] [PubMed] [Google Scholar]
  • 8.Kreitman RJ, Wilson WH, White JD, et al. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol. 2000;18:1622–1636. doi: 10.1200/JCO.2000.18.8.1622. [DOI] [PubMed] [Google Scholar]
  • 9.Kreitman RJ, Wilson WH, Bergeron K, et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med. 2001;345:241–247. doi: 10.1056/NEJM200107263450402. [DOI] [PubMed] [Google Scholar]
  • 10.Sampson JH, Akabani G, Archer GE, et al. Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. J Neurooncol. 2003;65:27–35. doi: 10.1023/A:1026290315809. [DOI] [PubMed] [Google Scholar]
  • 11.Weaver M, Laske DW. Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas. J Neurooncol. 2003;65:3–13. doi: 10.1023/A:1026246500788. [DOI] [PubMed] [Google Scholar]
  • 12.Leamon CP, Pastan I, Low PS. Cytotoxicity of folate-Pseudomonas exotoxin conjugates toward tumor cells. Contribution of translocation domain. J Biol Chem. 1993;268:24847–24854. [PubMed] [Google Scholar]
  • 13.Leamon CP, Low PS. Selective targeting of malignant cells with cytotoxin-folate conjugates. J Drug Target. 1994;2:101–112. doi: 10.3109/10611869409015898. [DOI] [PubMed] [Google Scholar]
  • 14.Atkinson SF, Bettinger T, Seymour LW, et al. Conjugation of folate via gelonin carbohydrate residues retains ribosomal-inactivating properties of the toxin and permits targeting to folate receptor positive cells. J Biol Chem. 2001;276:27930–27935. doi: 10.1074/jbc.M102825200. [DOI] [PubMed] [Google Scholar]
  • 15.Frankel AE, Powell BL, Hall PD, et al. Phase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia. Clin Cancer Res. 2002;8:1004–1013. [PubMed] [Google Scholar]
  • 16.Bagshawe KD, Sharma SK, Begent RH. Antibody-directed enzyme prodrug therapy (ADEPT) for cancer. Expert Opin Biol Ther. 2004;4:1777–1789. doi: 10.1517/14712598.4.11.1777. [DOI] [PubMed] [Google Scholar]
  • 17.Francis RJ, Sharma SK, Springer C, et al. A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours. Br J Cancer. 2002;87:600–607. doi: 10.1038/sj.bjc.6600517. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.de Graaf M, Boven E, Oosterhoff D, et al. A fully human anti-EpCAM scFv-beta-glucuronidase fusion protein for selective chemotherapy with a glucuronide prodrug. Br J Cancer. 2002;86:811–818. doi: 10.1038/sj.bjc.6600143. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Spooner RA, Friedlos F, Maycroft K, et al. A novel vascular endothelial growth factor-directed therapy that selectively activates cytotoxic prodrugs. Br J Cancer. 2003;88:1622–1630. doi: 10.1038/sj.bjc.6600911. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Lu JY, Lowe DA, Kennedy MD, Low PS. Folate-targeted enzyme prodrug cancer therapy utilizing penicillin-V amidase and a doxorubicin prodrug. J Drug Target. 1999;7:43–53. doi: 10.3109/10611869909085491. [DOI] [PubMed] [Google Scholar]
  • 21.Robinson MA, Charlton ST, Garnier P, et al. LEAPT: lectin-directed enzyme-activated prodrug therapy. Proc Natl Acad Sci USA. 2004;101:14527–14532. doi: 10.1073/pnas.0303574101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Sondel PM, Hank JA, Gan J, et al. Preclinical and clinical development of immunocytokines. Curr Opin Investig Drugs. 2003;4:696–700. [PubMed] [Google Scholar]
  • 23.Connor JP, Felder M, Hank J, et al. Ex vivo evaluation of anti-EpCAM immunocytokine huKS-IL2 in ovarian cancer. J Immunother. 2004;27:211–219. doi: 10.1097/00002371-200405000-00005. [DOI] [PubMed] [Google Scholar]
  • 24.Gillies SD, Lan Y, Williams S, et al. An anti-CD20-IL-2 immunocytokine is highly efficacious in a SCID mouse model of established human B lymphoma. Blood. 2005;105:3972–3978. doi: 10.1182/blood-2004-09-3533. [DOI] [PubMed] [Google Scholar]
  • 25.Melani C, Figini M, Nicosia D, et al. Targeting of interleukin 2 to human ovarian carcinoma by fusion with a single-chain Fv of antifolate receptor antibody. Cancer Res. 1998;58:4146–4154. [PubMed] [Google Scholar]
  • 26.Metelitsa LS, Gillies SD, Super M, et al. Antidisialoganglioside/granulocyte macrophage-colony-stimulating factor fusion protein facilitates neutrophil antibody-dependent cellular cytotoxicity and depends on FegammaRII (CD32) and Mac-1 (CD11b/CD18) for enhanced effector cell adhesion and azurophil granule exocytosis. Blood. 2002;99:4166–4173. doi: 10.1182/blood.V99.11.4166. [DOI] [PubMed] [Google Scholar]
  • 27.Lyu MA, Rosenblum MG. The immunocytokine scFv23/TNF sensitizes HER-2/neu-overexpressing SKBR-3 cells to tumor necrosis factor (TNF) via up-regulation of TNF receptor-1. Mol Cancer Ther. 2005;4:1205–1213. doi: 10.1158/1535-7163.MCT-05-0014. [DOI] [PubMed] [Google Scholar]
  • 28.Notter M, Willinger T, Erben U, Thiel E. Targeting of a B7-1 (CD80) immunoglobulin G fusion protein to acute myeloid leukemia blasts increases their costimulatory activity for autologous remission T cells. Blood. 2001;97:3138–3145. doi: 10.1182/blood.V97.10.3138. [DOI] [PubMed] [Google Scholar]
  • 29.Patten PA, Schellekens H. The immunogenicity of biopharmaceuticals. Lessons learned and consequences for protein drug development. Dev Biol (Basel). 2003;112:81–97. [PubMed] [Google Scholar]
  • 30.Hermeling S, Crommelin DJ, Schellekens H, Jiskoot W. Structure-immunogenicity relationships of therapeutic proteins. Pharm Res. 2004;21:897–903. doi: 10.1023/B:PHAM.0000029275.41323.a6. [DOI] [PubMed] [Google Scholar]
  • 31.Kolkman JA, Stemmer WP. Directed evolution of proteins by exon shuffling. Nat Biotechnol. 2001;19:423–428. doi: 10.1038/88084. [DOI] [PubMed] [Google Scholar]
  • 32.Schellekens H. Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin Ther. 2002;24:1720–1740. doi: 10.1016/S0149-2918(02)80075-3. [DOI] [PubMed] [Google Scholar]
  • 33.Caliceti P, Veronese FM. Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Adv Drug Deliv Rev. 2003;55:1261–1277. doi: 10.1016/S0169-409X(03)00108-X. [DOI] [PubMed] [Google Scholar]
  • 34.Deen WM, Lazzara MJ, Myers BD. Structural determinants of glomerular permeability. Am J Physiol Renal Physiol. 2001;281:F579–F596. doi: 10.1152/ajprenal.2001.281.4.F579. [DOI] [PubMed] [Google Scholar]
  • 35.Nishida K, Mihara K, Takino T, et al. Hepatic disposition characteristics of electrically charged macromolecules in rat in vivo and in the perfused liver. Pharm Res. 1991;8:437–444. doi: 10.1023/A:1015886708598. [DOI] [PubMed] [Google Scholar]
  • 36.Stockert RJ. The asialoglycoprotein receptor: relationships between structure, function, and expression. Physiol Rev. 1995;75:591–609. doi: 10.1152/physrev.1995.75.3.591. [DOI] [PubMed] [Google Scholar]
  • 37.Landers KA, Burger MJ, Tebay MA, et al. Use of multiple biomarkers for a molecular diagnosis of prostate cancer. Int J Cancer. 2005;114:950–956. doi: 10.1002/ijc.20760. [DOI] [PubMed] [Google Scholar]
  • 38.Silver DA, Pellicer I, Fair WR, et al. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3:81–85. [PubMed] [Google Scholar]
  • 39.Luthi-Carter R, Barczak AK, Speno H, Coyle JT. Molecular characterization of human brain N-acetylated alpha-linked acidic dipeptidase (NAALADase) J Pharmacol Exp Ther. 1998;286:1020–1025. [PubMed] [Google Scholar]
  • 40.Lu Y, Low PS. Folate-mediated delivery of macromolecular anticancer therapeutic agents. Adv Drug Deliv Rev. 2002;54:675–693. doi: 10.1016/S0169-409X(02)00042-X. [DOI] [PubMed] [Google Scholar]
  • 41.Mastrobattista E, Crommelin DJ, Wilsehut J, Storm G. Targeted liposomes for delivery of protein-based drugs into the cytoplasm of tumor cells. J Liposome Res. 2002;12:57–65. doi: 10.1081/LPR-120004777. [DOI] [PubMed] [Google Scholar]
  • 42.Becker A, Hessenius C, Lieha K, et al. Receptor-targeted optical imaging of tumors with near-infrared fluorescent ligands. Nat Biotechnol. 2001;19:327–331. doi: 10.1038/86707. [DOI] [PubMed] [Google Scholar]
  • 43.Langer M, Beck-Sickinger AG. Peptides as carrier for tumor diagnosis and treatment. Curr Med Chem Anticancer Agents. 2001;1:71–93. doi: 10.2174/1568011013354877. [DOI] [PubMed] [Google Scholar]
  • 44.Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–2342. doi: 10.1056/NEJMoa032691. [DOI] [PubMed] [Google Scholar]
  • 45.Ma J, Pulfer S, Li S, et al. Pharmacodynamic-mediated reduction of temozolomide tumor concentrations by the angiogenesis inhibitor TNP-470. Cancer Res. 2001;61:5491–5498. [PubMed] [Google Scholar]
  • 46.Jain RK. Molecular regulation of vessel maturation. Nat Med. 2003;9:685–693. doi: 10.1038/nm0603-685. [DOI] [PubMed] [Google Scholar]
  • 47.Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307:58–62. doi: 10.1126/science.1104819. [DOI] [PubMed] [Google Scholar]
  • 48.Christiansen J, Rajasekaran AK. Biological impediments to monoclonal antibody-based cancer immunotherapy. Mol Cancer Ther. 2004;3:1493–1501. [PubMed] [Google Scholar]
  • 49.Curnis F, Sacchi A, Corti A. Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. J Clin Invest. 2002;110:475–482. doi: 10.1172/JCI15223. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Curnis F, Gasparri A, Sacchi A, et al. Coupling tumor necrosis factor-alpha with alphaV integrin ligands improves its antineoplastic activity. Cancer Res. 2004;64:565–571. doi: 10.1158/0008-5472.CAN-03-1753. [DOI] [PubMed] [Google Scholar]
  • 51.Fujimori K, Covell DG, Fletcher JE, Weinstein JN. Modeling analysis of the global and microscopic distribution of immunoglobulin G, F(ab′)2, and Fab in tumors. Cancer Res. 1989;49:5656–5663. [PubMed] [Google Scholar]
  • 52.Juweid M, Neumann R, Paik C, et al. Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier. Cancer Res. 1992;52:5144–5153. [PubMed] [Google Scholar]
  • 53.Adams GP, Schier R, McCall AM, et al. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res. 2001;61:4750–4755. [PubMed] [Google Scholar]
  • 54.Langmuir VK, Mendonca HL, Woo DV. Comparisons between two monoclonal antibodies that bind to the same antigen but have differing affinities: uptake kinetics and 1251-antibody therapy efficacy in multicell spheroids. Cancer Res. 1992;52:4728–4734. [PubMed] [Google Scholar]
  • 55.Saga T, Neumann RD, Heya T, et al. Targeting cancer micrometastases with monoclonal antibodies: a binding-site barrier. Proc Natl Acad Sci USA. 1995;92:8999–9003. doi: 10.1073/pnas.92.19.8999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Fracasso G, Colombatti M. Effect of therapeutic macromolecules in spheroids. Crit Rev Oncol Hematol. 2000;36:159–178. doi: 10.1016/S1040-8428(00)00084-6. [DOI] [PubMed] [Google Scholar]
  • 57.Graff CP, Wittrup KD. Theoretical analysis of antibody targeting of tumor spheroids: importance of dosage for penetration, and affinity for retention. Cancer Res. 2003;63:1288–1296. [PubMed] [Google Scholar]
  • 58.Le Roy C, Wrana JL. Clathrin- and non-clathrin-mediated endocytic regulation of cell signalling. Nat Rev Mol Cell Biol. 2005;6:112–126. doi: 10.1038/nrm1571. [DOI] [PubMed] [Google Scholar]
  • 59.Leamon CP, Low PS. Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis. Proc Natl Acad Sci USA. 1991;88:5572–5576. doi: 10.1073/pnas.88.13.5572. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Wellhoner HH, Neville DM, Srinivasachar K, Erdmann G. Uptake and concentration of bioactive macromolecules by K562 cells via the transferrin cycle utilizing an acid-labile transferrin conjugate. J Biol Chem. 1991;266:4309–4314. [PubMed] [Google Scholar]
  • 61.El-Sayed ME, Hoffman AS, Stayton PS. Smart polymeric carriers for enhanced intracellular delivery of therapentic macromolecules. Expert Opin Biol Ther. 2005;5:23–32. doi: 10.1517/14712598.5.1.23. [DOI] [PubMed] [Google Scholar]
  • 62.Mastrobattista E, Koning GA, van Bloois L, et al. Functional characterization of an endosome-disruptive peptide and its application in cytosolic delivery of immunoliposome-entrapped proteins. J Biol Chem. 2002;277:27135–27143. doi: 10.1074/jbc.M200429200. [DOI] [PubMed] [Google Scholar]
  • 63.Kakudo T, Chaki S, Futaki S, et al. Transferrin-modified liposomes equipped with a pH-sensitive fusogenic peptide: an artificial viral-like delivery system. Biochemistry. 2004;43:5618–5628. doi: 10.1021/bi035802w. [DOI] [PubMed] [Google Scholar]
  • 64.Berg K, Selbo PK, Prasmickaite L, et al. Photochemical internalization: a novel technology for delivery of macromolecules into cytosol. Cancer Res. 1999;59:1180–1183. [PubMed] [Google Scholar]
  • 65.Selbo PK, Sivam G, Fodstad O, et al. In vivo documentation of photochemical internalization, a novel approach to site specific cancer therapy. Int J Cancer. 2001;92:761–766. doi: 10.1002/1097-0215(20010601)92:5<761::AID-IJC1238>3.0.CO;2-4. [DOI] [PubMed] [Google Scholar]
  • 66.Selbo PK, Sivam G, Fodstad O, et al. Photochemical internalisation increases the cytotoxic effect of the immunotoxin MOC31-gelonin. Int J Cancer. 2000;87:853–859. doi: 10.1002/1097-0215(20000915)87:6<853::AID-IJC15>3.0.CO;2-0. [DOI] [PubMed] [Google Scholar]
  • 67.Hogset A, Prasmickaite L, Selbo PK, et al. Photochemical internalisation in drug and gene delivery. Adv Drug Deliv Rev. 2004;56:95–115. doi: 10.1016/j.addr.2003.08.016. [DOI] [PubMed] [Google Scholar]
  • 68.Brem S. Angiogenesis and cancer control: from concept to therapeutic trial. Cancer Control. 1999;6:436–458. [PubMed] [Google Scholar]
  • 69.Adessi C, Soto C. Converting a peptide into a drug: strategies to improve stability and bioavailability. Curr Med Chem. 2002;9:963–978. doi: 10.2174/0929867024606731. [DOI] [PubMed] [Google Scholar]
  • 70.Binetruy-Tournaire R, Demangel C, Malavaud B, et al. Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis. EMBO J. 2000;19:1525–1533. doi: 10.1093/emboj/19.7.1525. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71.Reiher FK, Volpert OV, Jimenez B, et al. Inhibition of tumor growth by systemic treatment with thrombospondin-1 peptide mimetics. Int J Cancer. 2002;98:682–689. doi: 10.1002/ijc.10247. [DOI] [PubMed] [Google Scholar]
  • 72.Koivunen E, Wang B, Ruoslahti E. Phage libraries displaying cyclic peptides with different ring sizes: ligand specificities of the RGD-directed integrins. Biotechnology (NY). 1995;13:265–270. doi: 10.1038/nbt0395-265. [DOI] [PubMed] [Google Scholar]
  • 73.Kumar CC, Malkowski M, Yin Z, et al. Inhibition of angiogenesis and tumor growth by SCH221153, a dual alpha(v)beta3 and alpha(v)beta5 integrin receptor antagonist. Cancer Res. 2001;61:2232–2238. [PubMed] [Google Scholar]
  • 74.Pasqualini R, Koivunen E, Kain R, et al. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res. 2000;60:722–727. [PMC free article] [PubMed] [Google Scholar]
  • 75.Koivunen E, Arap W, Valtanen H, et al. Tumor targeting with a selective gelatinase inhibitor. Nat Biotechnol. 1999;17:768–774. doi: 10.1038/11703. [DOI] [PubMed] [Google Scholar]
  • 76.Laakkonen P, Akerman ME, Biliran H, et al. Antitumor activity of a homing peptide that targets tumor lymphatics and tumor cells. Proc Natl Acad Sci USA. 2004;101:9381–9386. doi: 10.1073/pnas.0403317101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 77.Froidevaux S, Eberle AN. Somatostatin analogs and radiopeptides in cancer therapy. Biopolymers. 2002;66:161–183. doi: 10.1002/bip.10256. [DOI] [PubMed] [Google Scholar]
  • 78.Kanashiro CA, Schally AV, Groot K, et al. Inhibition of mutant p53 expression and growth of DMS-153 small cell lung carcinoma by antagonists of growth hormone-releasing hormone and bombesin. Proc Natl Acad Sci USA. 2003;100:15836–15841. doi: 10.1073/pnas.2536558100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 79.Stangelberger A, Schally AV, Varga JL, et al. Inhibitory effect of antagonists of bombesin and growth hormone-releasing hormone on orthotopic and intraosseous growth and invasiveness of PC-3 human prostate cancer in nude mice. Clin Cancer Res. 2005;11:49–57. [PubMed] [Google Scholar]
  • 80.Schally AV, Comaru-Schally AM, Plonowski A, et al. Peptide analogs in the therapy of prostate cancer. Prostate. 2000;45:158–166. doi: 10.1002/1097-0045(20001001)45:2<158::AID-PROS10>3.0.CO;2-K. [DOI] [PubMed] [Google Scholar]
  • 81.Colombo G, Curnis F, De Mori GM, et al. Structure-activity relationships of linear and cyclic peptides containing the NGR tumor-homing motif. J Biol Chem. 2002;277:47891–47897. doi: 10.1074/jbc.M207500200. [DOI] [PubMed] [Google Scholar]
  • 82.Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science. 1998;279:377–380. doi: 10.1126/science.279.5349.377. [DOI] [PubMed] [Google Scholar]
  • 83.Chen Y, Xu X, Hong S, et al. RGD-Tachyplesin inhibits tumor growth. Cancer Res. 2001;61:2434–2438. [PubMed] [Google Scholar]
  • 84.Ellerby HM, Arap W, Ellerby LM, et al. Anti-cancer activity of targeted pro-apoptotic peptides. Nat Med. 1999;5:1032–1038. doi: 10.1038/12469. [DOI] [PubMed] [Google Scholar]
  • 85.de Jong M, Kwekkeboom D, Valkema R, Krenning EP. Radiolabelled peptides for tumour therapy: current status and future directions. Plenary lecture at the EANM 2002. Eur J Nucl Med Mol Imaging. 2003;30:463–469. doi: 10.1007/s00259-002-1107-8. [DOI] [PubMed] [Google Scholar]
  • 86.Scopinaro F, De Vincentis G, Corazziari E, et al. Detection of colon cancer with 99mTc-labeled bombesin derivative (99mTc-leu13-BN1) Cancer Biother Radiopharm. 2004;19:245–252. doi: 10.1089/108497804323072020. [DOI] [PubMed] [Google Scholar]
  • 87.Varvarigou A, Bouziotis P, Zikos C, et al. Gastrin-releasing peptide (GRP) analogues for cancer imaging. Cancer Biother Radiopharm. 2004;19:219–229. doi: 10.1089/108497804323072002. [DOI] [PubMed] [Google Scholar]
  • 88.Schally AV, Nagy A. New approaches to treatment of various cancers based on cytotoxic analogs of LHRH, somatostatin and bombesin. Life Sci. 2003;72:2305–2320. doi: 10.1016/S0024-3205(03)00113-9. [DOI] [PubMed] [Google Scholar]
  • 89.Schally AV, Nagy A. Chemotherapy targeted to cancers through tumoral hormone receptors. Trends Endocrinol Metab. 2004;15:300–310. doi: 10.1016/j.tem.2004.07.002. [DOI] [PubMed] [Google Scholar]
  • 90.Leuschner C, Enright FM, Gawronska-Kozak B, Hansel W. Human prostate cancer cells and xenografts are targeted and destroyed through luteinizing hormone releasing hormone receptors. Prostate. 2003;56:239–249. doi: 10.1002/pros.10259. [DOI] [PubMed] [Google Scholar]
  • 91.Gawronska B, Leuschner C, Enright FM, Hansel W. Effects of a lytic peptide conjugated to beta HCG on ovarian cancer: studies in vitro and in vivo. Gynecol Oncol. 2002;85:45–52. doi: 10.1006/gyno.2001.6558. [DOI] [PubMed] [Google Scholar]
  • 92.Curnis F, Sacchi A, Borgna L, et al. Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13) Nat Biotechnol. 2000;18:1185–1190. doi: 10.1038/81183. [DOI] [PubMed] [Google Scholar]
  • 93.Bauer W, Briner U, Doepfner W, et al. SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci. 1982;31:1133–1140. doi: 10.1016/0024-3205(82)90087-X. [DOI] [PubMed] [Google Scholar]
  • 94.Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev. 2003;24:389–427. doi: 10.1210/er.2002-0007. [DOI] [PubMed] [Google Scholar]
  • 95.Hamel E. Interactions of antimitotic peptides and depsipeptides with tubulin. Biopolymers. 2002;66:142–160. doi: 10.1002/bip.10255. [DOI] [PubMed] [Google Scholar]
  • 96.Edelman MJ, Gandara DR, Hansner P, et al. Phase 2 study of cryptophycin 52 (LY355703) in patients previously treated with platinum based chemotherapy for advanced non-small cell lung cancer. Lung Cancer. 2003;39:197–199. doi: 10.1016/S0169-5002(02)00511-1. [DOI] [PubMed] [Google Scholar]
  • 97.Marks RS, Graham DL, Sloan JA, et al. A phase II study of the dolastatin 15 analogue LU 103793 in the treatment of advanced non-small-cell lung cancer. Am J Clin Oncol. 2003;26:336–337. doi: 10.1097/00000421-200308000-00005. [DOI] [PubMed] [Google Scholar]
  • 98.Law CL, Cerveny CG, Gordon KA, et al. Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates. Clin Cancer Res. 2004;10:7842–7851. doi: 10.1158/1078-0432.CCR-04-1028. [DOI] [PubMed] [Google Scholar]
  • 99.Doronina SO, Toki BE, Torgov MY, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol. 2003;21:778–784. doi: 10.1038/nbt832. [DOI] [PubMed] [Google Scholar]
  • 100.Francisco JA, Cerveny CG, Meyer DL, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003;102:1458–1465. doi: 10.1182/blood-2003-01-0039. [DOI] [PubMed] [Google Scholar]
  • 101.Bhaskar V, Law DA, Ibsen E, et al. E-selectin up-regulation allows for targeted drug delivery in prostate cancer. Cancer Res. 2003;63:6387–6394. [PubMed] [Google Scholar]
  • 102.Afar DE, Bhaskar V, Ibsen E, et al. Preclinical validation of anti-TMEFF2-auristatin E-conjugated antibodies in the treatment of prostate cancer. Mol Cancer Ther. 2004;3:921–932. [PubMed] [Google Scholar]
  • 103.Low PS, Antony AC. Folate receptor-targeted drugs for cancer and inflammatory diseases. Adv Drug Deliv Rev. 2004;56:1055–1058. doi: 10.1016/j.addr.2004.02.003. [DOI] [PubMed] [Google Scholar]
  • 104.Paulos CM, Reddy JA, Leamon CP, et al. Ligand binding and kinetics of folate receptor recycling in vivo: impact on receptor-mediated drug delivery. Mol Pharmacol. 2004;66:1406–1414. doi: 10.1124/mol.104.003723. [DOI] [PubMed] [Google Scholar]
  • 105.Lu Y, Sega E, Low PS. Folate receptor-targeted immunotherapy: induction of humoral and cellular immunity against hapten-decorated cancer cells. Int J Cancer. 2005;116:710–719. doi: 10.1002/ijc.21126. [DOI] [PubMed] [Google Scholar]
  • 106.Shinoda T, Takagi A, Maeda A, et al. In vivo fate of folate-BSA in non-tumor- and tumor-bearing mice. J Pharm Sci. 1998;87:1521–1526. doi: 10.1021/js980215v. [DOI] [PubMed] [Google Scholar]
  • 107.Ward CM, Acheson N, Seymour LW. Folic acid targeting of protein conjugates into ascites tumour cells from ovarian cancer patients. J Drug Target. 2000;8:119–123. doi: 10.3109/10611860008996857. [DOI] [PubMed] [Google Scholar]
  • 108.Roy EJ, Gawlick U, Orr BA, Kranz DM. Folate-mediated targeting of T cells to tumors. Adv Drug Deliv Rev. 2004;56:1219–1231. doi: 10.1016/j.addr.2004.01.006. [DOI] [PubMed] [Google Scholar]
  • 109.Kennedy MD, Jallad KN, Thompson DH, et al. Optical imaging of metastatic tumors using a folate-targeted fluorescent probe. J Biomed Opt. 2003;8:636–641. doi: 10.1117/1.1609453. [DOI] [PubMed] [Google Scholar]
  • 110.Lu Y, Low PS. Folate targeting of haptens to cancer cell surfaces mediates immunotherapy of syngeneic murine tumors. Cancer Immunol Immunother. 2002;51:153–162. doi: 10.1007/s00262-002-0266-6. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from The AAPS Journal are provided here courtesy of American Association of Pharmaceutical Scientists

RESOURCES